Eli Lilly and Company vs AbbVie
LLY
Eli Lilly and Company NYSE
$1,108.31 ▲ 0.11%
VS
ABBV
AbbVie Inc NYSE
$233.33 ▼ 0.61%
Last updated: (1m ago) • LLY at $1,108.31, ABBV at $233.33
CleaRank Financial AI • Data from TwelveData & CoinGecko
Reviewed by CleaRank editorial team. Data refreshed daily. Not financial advice.
Comparative Analysis
LLY wins due to its superior growth trajectory and exceptional capital efficiency compared to ABBV. While ABBV trades at a significantly higher valuation multiple, it fails to match the explosive revenue expansion and robust profitability demonstrated by LLY. LLY’s ability to maintain a 34.99% net profit margin while scaling revenue at 55.5% makes it the clear choice for growth-oriented institutional portfolios. Conversely, ABBV’s negative return on equity and compressed margins suggest significant operational headwinds that investors should avoid. LLY offers a more compelling risk-reward profile in the current market environment.
Key Differentiator
The decisive factor is the stark contrast in capital efficiency and growth. LLY’s 107.46% ROE against ABBV’s negative ROE creates a fundamental chasm that cannot be ignored. LLY is a compounding machine, while ABBV is currently an inefficient operator struggling to justify its high valuation.
Joint Outlook
The 6-12 month outlook for LLY remains bullish, provided it continues to execute on its growth strategy and maintains its current margin profile. We expect LLY to continue outperforming the broader sector as it scales its operations and captures further market share. The stock is well-positioned to test its 52-week highs if the current momentum persists through the next two quarters.
Price Analysis Comparison
Valuation Metrics
| Metric | LLY | ABBV |
|---|---|---|
| P/E Ratio | 39.22 | 112.20 |
| Market Cap | 987.23B | 414.77B |
| Price/Sales | 13.60 | 6.47 |
| Price/Book | 31.56 | -62.67 |
| EV/EBITDA | 28.19 | 15.71 |
| Dividend Yield | N/A | N/A |
LLY is the more attractively valued asset, trading at a P/E of 39.22 compared to ABBV’s prohibitive 112.2 multiple. This massive valuation gap suggests that the market is pricing in significant future struggles for ABBV, whereas LLY’s premium is justified by its massive revenue growth. Investors are paying a much higher price for every dollar of earnings in ABBV, which provides a poor margin of safety. LLY’s valuation reflects a high-growth compounder, while ABBV’s valuation appears stretched relative to its underlying financial health. The disparity in these multiples highlights a clear divergence in investor confidence between the two firms.
Profitability & Efficiency
| Metric | LLY | ABBV |
|---|---|---|
| Rev. Growth (Qtly) | 55.50% | 12.40% |
| Profit Margin | 34.99% | 5.79% |
| Return on Equity | 107.46% | -129.68% |
| Return on Assets | 20.74% | 10.03% |
| Debt/Equity | 139.02 | -11.03 |
LLY demonstrates elite capital efficiency with a 34.99% net profit margin and a remarkable 107.46% return on equity. These figures indicate that LLY is generating immense value from its capital base, far outperforming ABBV. ABBV’s 5.79% net profit margin and negative return on equity signal significant operational inefficiencies and potential balance sheet strain. LLY is clearly the more profitable and efficient operator in this head-to-head comparison.
Earnings Reality Check
LLY
Analysis loading...
ABBV
Analysis loading...
Technical Indicators
| Indicator | LLY | ABBV |
|---|---|---|
| RSI (14) | 59.31 | 65.30 |
| 50-Day MA | $1,021.05 | $213.20 |
| 200-Day MA | $971.66 | $220.87 |
LLY is trading in a strong uptrend, comfortably above its 50-day SMA of $1021.05 and 200-day SMA of $971.66. With an RSI of 59.31, the stock has room to run before hitting overbought territory, suggesting sustained momentum. ABBV is also in an uptrend, trading above its 50-day SMA of $213.20, but its RSI of 65.3 and high stochastic reading of 81.91 indicate it is approaching overbought conditions. Note: In strong trend phases, oscillators can remain overbought for extended periods, but ABBV’s proximity to its 52-week high of $244.81 suggests limited immediate upside compared to LLY.
AI Analyst Sentiment
LLY
Hold
Technical Score: 50/100
ABBV
Hold
Technical Score: 55/100
Institutional sentiment heavily favors LLY, as evidenced by its strong price action and massive market capitalization growth. The market is rewarding LLY’s consistent execution, while ABBV is seeing more cautious positioning given its valuation and profitability concerns. Smart money is clearly rotating into LLY to capture its superior growth and margin expansion. ABBV remains a defensive position that is currently struggling to attract the same level of conviction from institutional buyers.
Note: While ABBV shows stronger short-term technical momentum (Hold 55/100), the AI comparative analysis favors LLY (Hold 50/100) based on its overall trend structure, fundamentals, and risk-adjusted outlook.
Risk Stratification
| Metric | LLY | ABBV |
|---|---|---|
| Beta (Volatility) | 0.52 | 0.31 |
| Sharpe Ratio | 0.55 | 0.60 |
The primary risk for LLY is its high valuation, which leaves little room for error if growth rates decelerate or if competitive pressures intensify. Any miss on earnings expectations could lead to a sharp correction given the high expectations baked into the current price. Additionally, regulatory scrutiny on high-growth pharmaceutical products remains a constant threat to LLY’s long-term margin profile. These risks are significant but are currently mitigated by the company’s strong fundamental performance.
Comparative ProTips
- Always prioritize ROE when comparing pharmaceutical companies to ensure management is effectively deploying capital.
- Use the RSI and Stochastic indicators to time entries, but remember that in strong bull markets, these can stay overbought for months.
- Focus on net profit margins to distinguish between companies that are truly profitable and those that are just growing revenue at the expense of the bottom line.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative 3% Aggressive
Portfolio Value
$ ✎
Position Size: $200 - $300 per asset
LLY
Current: $1,108.31
ENTRY ZONES
Conservative
$1,052.89
Aggressive
$1,108.31
RISK MANAGEMENT
STOP LOSS
$1,021.31
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$1,105.54
+10%
$1,158.18
+15%
$1,210.83
ABBV
Current: $233.33
ENTRY ZONES
Conservative
$221.66
Aggressive
$233.33
RISK MANAGEMENT
STOP LOSS
$215.01
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$232.74
+10%
$243.82
+15%
$254.91
Calculate Your Trade
ℹ️ Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored LLY based on current technical setup. This is valid for the specified timeframe only.